Item 7.01. Regulation FD Disclosure.

On September 27, 2021, Sarepta Therapeutics, Inc. (the "Company") issued a press release to provide a program update for its MOMENTUM study of SRP-5051 in patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping. A copy of the Company's press release is being furnished as Exhibit 99.1

The information in this report, furnished pursuant to Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this report.

Item 9.01. Financial Statements and Exhibits.




(d) Exhibits



Exhibit No.   Description
   99.1         Press Release dated September 27, 2021: Sarepta Therapeutics to
              Initiate Part B of MOMENTUM Study of SRP-5051 in Patients with Duchenne
              Muscular Dystrophy Amenable to Exon 51 Skipping Following Positive
              Interactions with FDA
    104       The cover page from this Current Report on Form 8-K of Sarepta
              Therapeutics, Inc., formatted in Inline XBRL and included as Exhibit
              101




                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses